Revista chilena de cardiología
versión ISSN 0718-8560
ORTIZ, María Clara; CARRILLO, Diana Cristina y CEPEDA, Magda Cristina. Predictors of major adverse cardiac after off label use of drug eluting stents in coronary angioplasty. Rev Chil Cardiol [online]. 2012, vol.31, n.2, pp. 112-117. ISSN 0718-8560. doi: 10.4067/S0718-85602012000200005.
Background: The off label use of drug eluting stents (DES) is associated to a greater risk of adverse events. Aim: to determine predictors of major adverse cardiac events (MACE) at one year after the off label implantation of DES. Method: an analysis of a cohort obtained from an institutional PTCA registry was performed. Adults who had one or more DES implanted on off label indications were included. A multivariate model was developed in order to identify predictors of complications associated to off label use of DES. Results: 603 patients, mean age 60 years, 74% males, were included. After one year of follow up, mortality was 0.33%, ST elevation MI developed in 3.0%, intra-stent thrombosis in 1.9% and revascularization of the target vessel was performed in 6.8%. Dislipide-mia (OR 2.2, [95% C.I. 1.2^.1]) and peripheral vascular disease (OR 5.7, [2.0-16.2%]) were associated to a greater probability of MACE. Use of DES in ST elevation MI was associated to a decreased probability of MACE (OR 0.40, [0.17-0.95]). A reference vessel diameter <2.5mm (OR 2.2 [0.8-6.1%]) or lesions >35 mm in length (OR 0.99 [0.99-1.1]) were not predictive of MACE. The same was true for other angiographic variables. Conclusion: The use of DES in off label indications was not associated to an increased development of MACE. Dislipidemia and peripheral vascular disease were independent predictors of MACE.